Self‐Assembling Peptide‐Adjuvant Conjugate (SaPAC) Platform for Precision Cancer Immunotherapy
ABSTRACT Peptide cancer vaccines often suffer from poor lymphatic drainage, limited antigen‐presenting cell uptake, and weak innate immune activation. To overcome these barriers, we engineered the Self‐Assembling Peptide‐Adjuvant Conjugate (SaPAC) platform, which covalently links neoantigen epitopes to the TLR7 agonist...